Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Sept. 28 — The FDA is issuing fewer enforcement letters to companies over drug promotions in 2016 than in previous years, a top FDA official said Sept. 27.
Speaking at a Food and Drug Law Institute conference in Washington, Thomas Abrams, director of the Food and Drug Administration's Office of Prescription Drug Promotion (OPDP), acknowledged that there “are not a lot of enforcement letters so far this year.”
The OPDP issues warning letters and untitled letters to companies for drug marketing that doesn't meet the truthful, balanced and not-misleading promotional standard.
An untitled letter cites violations that don't meet the threshold of regulatory significance for a warning letter, according to the agency's regulatory procedures manual. Such letters often are used for drug promotion violations.
As of Sept. 16, the OPDP had issued only four enforcement letters in 2016 for drug marketing violations (14 PLIR 1314, 9/23/16). Three of those were untitled letters and one was a warning letter. In 2015, OPDP issued a total of nine enforcement letters.
Abrams stressed that the decrease in the numbers of letters being issued doesn't mean a lower level of enforcement on the agency's part.
Warning and untitled letters are “just one component of our multi-faceted approach to achieve the objective of having nonmisleading, truthful, and balanced promotion,” he said.
Other facets include developing guidance documents, reviewing draft product labeling and reviewing core launch materials.
“We will work on issuing guidances on promotional issues,” he said, with the goal of achieving voluntary compliance.
Abrams advised companies to build in extra time when they submit launch materials to OPDP.
OPDP receives 90,000 pre-launch promotional pieces for review each year, and its goal is to review companies' core launch materials within 45 days.
“We had been meeting that goal,” Abrams said, but recent submissions to the agency “have presented more complex issues requiring a deeper level of review and more consultation with our colleagues in different offices.”
“It's not like they're on the back burner,” he said. “We're digging down into complex issues.”
Abrams said companies should stay in close communication with the agency about their submissions.
“Talk to us about time frames,” he said, and “let your reviewer know that launch materials are coming.”
In addition, he said, companies should identify to the reviewer what the most important materials in the submission are, so the agency can work on those first.
He also said companies need to make sure their submissions are complete. “What we have seen sometimes are incomplete submissions including product claims without references or references that aren't annotated.”
Submission of unsupported claims really delays the process, Abrams said.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)